EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Progress in Virotherapy: Application and Future Prospects in Head and Neck Cancer

Yoshiaki Yura, Masakazu Hamada

International Journal of Molecular Sciences · 27.07.2026 · 27 (15) · 6682

DOI: 10.3390/ijms27156682 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.07.2026. Verfasst von Yoshiaki Yura und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral & Maxillofacial Oncology and Surgery, Graduate School of Dentistry, The University of Osaka, Suita 565-0871, Osaka, Japan. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Head and Neck Neoplasms. Die Arbeit nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Virus-based cancer therapy (virotherapy) is currently being researched as a novel form of immunotherapy and has already entered the clinical application phase. Among various types of virotherapy, oncolytic virotherapy involves infecting tumors with tumor-selective viruses, such as herpes simplex virus, adenoviruses, and vaccinia virus, and utilizing their replicative capacity to induce cell destruction within tumors. In addition, this therapy aims to enhance tumor immunity by changing the tumor microenvironment through viral infection. Genetic deletion in viruses is used to reduce their virulence and confer tumor selectivity, while the expression of foreign genes is utilized to enhance antitumor effects. Oncolytic viruses for head and neck cancer (HNC) are administered locally or systemically and are sometimes used as adjuvant therapy or in combination with immune checkpoint inhibitors. Another form of virotherapy involves non-replicating viruses, which are used to produce antitumor cytokines or as cancer vaccines expressing tumor antigens. Research on the efficacy of cancer vaccines in preventing postoperative recurrence is currently underway. A number of challenges have yet to be overcome for further advances in virotherapy, including the efficient delivery of viruses to tumor cells, avoiding viral inactivation in the bloodstream, ensuring efficient replication of the virus, and enhancing antitumor immunity. The development of effective strategies based on the findings of clinical studies will lead to improvements in virotherapy for HNC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyHead and Neck NeoplasmsHumansOncolytic VirusesCancer VaccinesAnimalsImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

adenovirusescancer vaccineclinical trialshead and neck cancerherpes simplex virusnon-replicating virusoncolytic virusvaccinia virusvirotherapy

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Department of Oral & Maxillofacial Oncology and Surgery, Graduate School of Dentistry, The University of Osaka, Suita 565-0871, Osaka, Japan.

Zitieren

APA

Yura, Y., & Hamada, M. (2026). Clinical Progress in Virotherapy: Application and Future Prospects in Head and Neck Cancer. International Journal of Molecular Sciences, 27(15), 6682. https://doi.org/10.3390/ijms27156682

Vancouver

Yura Y, Hamada M. Clinical Progress in Virotherapy: Application and Future Prospects in Head and Neck Cancer. International Journal of Molecular Sciences. 2026;27(15):6682. doi:10.3390/ijms27156682

BibTeX
@article{Yura2026,
  author = {Yura, Yoshiaki and Hamada, Masakazu},
  title = {Clinical Progress in Virotherapy: Application and Future Prospects in Head and Neck Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {15},
  pages = {6682},
  doi = {10.3390/ijms27156682}
}
Kostenlos starten →